Patents by Inventor James E. Audia

James E. Audia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tetrahydro-beta-carbolines
    Patent number: 5629317
    Abstract: The present invention provides novel tetrahydro-beta-carboline compounds having useful central nervous system activity. Further, there is provided tetrahydro-beta-carboline related compounds which are useful intermediates and have beneficial central nervous system activity. The invention provides formulations and methods for using the novel tetrahydro-beta-carboline and related compounds. Such compounds are particularly useful for the modulation of a 5-HT.sub.2B receptor.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: May 13, 1997
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Stephen R. Baker, Jesus E. Carrera, Carlos L. Peteira, Concepcion P. Tercero
  • Compounds having effects on serotonin-related systems
    Patent number: 5627196
    Abstract: A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: May 6, 1997
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, David J. Hibschman, Joseph H. Krushinski, Jr., Thomas E. Mabry, Jeffrey S. Nissen, Kurt Rasmussen, Vincent P. Rocco, John M. Schaus, Dennis C. Thompson, David T. Wong
  • 5.alpha.-reductase inhibitors
    Patent number: 5622961
    Abstract: A series of benzoquinolin-3-ones are pharmaceuticals effective in treating conditions consequent on both Type I and Type II 5.alpha.-reductase.
    Type: Grant
    Filed: May 11, 1995
    Date of Patent: April 22, 1997
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Loretta A. McQuaid, Blake L. Neubauer, Vincent P. Rocco
  • 5.alpha.-reductase inhibitors
    Patent number: 5622962
    Abstract: A series of benzoquinolin-3-ones are pharmaceuticals effective in treating conditions consequent on both Type I and Type II 5.alpha.-reductase.
    Type: Grant
    Filed: May 11, 1995
    Date of Patent: April 22, 1997
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Loretta A. McQuaid, Blake L. Neubauer, Vincent P. Rocco
  • Compounds having effects on serotonin-related systems
    Patent number: 5614523
    Abstract: A series of hetero-oxy alkanamines are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1.sub.A receptor. The compounds are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: March 25, 1997
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Joseph H. Krushinski, Jr., Kurt Rasmussen, Vincent P. Rocco, John M. Schaus, Dennis C. Thompson, David T. Wong
  • Syntheis of benzoquinolinones
    Patent number: 5574160
    Abstract: A 1-pot process for preparing 10b-methyl-3-oxo-benzo[f] quinolines.
    Type: Grant
    Filed: May 18, 1995
    Date of Patent: November 12, 1996
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, James J. Droste, Perry C. Heath, Leland O. Weigel
  • Methods for inhibiting bone loss
    Patent number: 5550134
    Abstract: The present invention provides methods of inhibiting bone loss in mammals via the administration to a mammal in need of such treatment an effective amount of a compound from a series of benzoquinolin-3-ones. Such compounds also are sequentially or concurrently coadministered with a bone antiresorptive agent or a bone anabolic agent.
    Type: Grant
    Filed: May 10, 1995
    Date of Patent: August 27, 1996
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Blake L. Neubauer
  • Benzo(F)quinolinones
    Patent number: 5541190
    Abstract: This invention relates to hexa- and octahydrobenzo[f]quinolin-3-ones, pharmaceutical formulations containing those compounds and methods of their use as steroid 5.alpha.-reductase inhibitors.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: July 30, 1996
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Kenneth S. Hirsch, Charles D. Jones, David E. Lawhorn, Loretta A. McQuaid, Leland O. Weigel
  • Tetrahydro-pyrido-indole
    Patent number: 5538981
    Abstract: The present invention provides novel tetrahydrobeta-carboline compounds and intermediates having useful central nervous system activity. The invention further provides formulations and methods for using the novel tetrahydrobeta-carboline compounds.
    Type: Grant
    Filed: May 10, 1995
    Date of Patent: July 23, 1996
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, James J. Droste, Deborah A. Evrard
  • Tetrahydro-pyrido-indole
    Patent number: 5538980
    Abstract: The present invention provides novel tetrahydro-beta-carboline compounds and intermediates having useful central nervous system activity.
    Type: Grant
    Filed: May 10, 1995
    Date of Patent: July 23, 1996
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, James J. Droste, Deborah A. Evrard
  • 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT.sub.1F agonists
    Patent number: 5521197
    Abstract: This invention provides novel 5-HT.sub.1F agonists which are useful for the treatment of migraine and associated disorders having the following formula: ##STR1## wherein A, B, X, Y, Ar and n are defined in the specification.
    Type: Grant
    Filed: December 1, 1994
    Date of Patent: May 28, 1996
    Assignee: Eli Lilly and Company
    Inventor: James E. Audia
  • 5-HT.sub.1F agonists for the treatment of migraine
    Patent number: 5521196
    Abstract: This invention provides novel 5-HT.sub.1F agonists which are useful for the treatment of migraine and associated disorders.
    Type: Grant
    Filed: October 5, 1994
    Date of Patent: May 28, 1996
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Jeffrey S. Nissen
  • Tetrahydro-beta-carbolines
    Patent number: 5508284
    Abstract: The present invention provides novel tetrahydro-beta-carboline compounds having useful central nervous system activity. Further, there is provided 3-ethanamine and 3-ethanamine related compounds which are useful intermediates and have beneficial central nervous system activity. The invention provides formulations and methods for using the novel tetrahydro-beta-carboline and related compounds.
    Type: Grant
    Filed: May 23, 1995
    Date of Patent: April 16, 1996
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, James J. Droste, Deborah A. Evrard, Pawel Fludzinski, Gwyn L. Murdoch, David L. Nelson
  • Tetrahydro-.beta.-carbolines
    Patent number: 5500431
    Abstract: The present invention provides tetrahydro-betacarboline compounds having useful central nervous system activity.
    Type: Grant
    Filed: March 11, 1994
    Date of Patent: March 19, 1996
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, James J. Droste, Deborah A. Evrard, Pawel Fludzinski, Gwyn L. Murdoch, David L. Nelson
  • Benzo[f]quinolinones
    Patent number: 5495021
    Abstract: This invention relates to hexa- and octahydrobenzo[f]quinolin-3-ones, pharmaceutical formulations containing those compounds and methods of their use as steroid 5.alpha.-reductase inhibitors.
    Type: Grant
    Filed: April 6, 1994
    Date of Patent: February 27, 1996
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, David E. Lawhorn, Leland O. Weigel
  • Tetrahydro-pyrido-indole
    Patent number: 5488053
    Abstract: The present invention provides pentacyclic pyrido[3,4-b]indoles having useful central nervous system activity.
    Type: Grant
    Filed: March 11, 1994
    Date of Patent: January 30, 1996
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, James J. Droste, Deborah A. Evrard
  • Reduced phenanthrenes
    Patent number: 5430157
    Abstract: A series of tetrahydrophenanthrenes are useful as inhibitors of 5.alpha.-reductase.
    Type: Grant
    Filed: December 13, 1993
    Date of Patent: July 4, 1995
    Assignee: Eli Lilly and Company
    Inventor: James E. Audia
  • Reduced phenanthrenes
    Patent number: 5356935
    Abstract: A series of dihydrophenanthreneones and tetrahydrophenanthreneones are useful as inhibitors of 5.alpha.-reductase, and a series of hexahydrophenanthreneones are useful as intermediates for preparing such pharmaceuticals.
    Type: Grant
    Filed: December 13, 1993
    Date of Patent: October 18, 1994
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Thomas C. Britton, Patrick G. Spinazze
  • Benzo[F]quinolinones
    Patent number: 5334767
    Abstract: This invention relates to hexa- and octahydrobenzo [f]quinolin-3-ones, pharmaceutical formulations containing those compounds and methods of their use as steroid 5.alpha.-reductase inhibitors.
    Type: Grant
    Filed: April 23, 1993
    Date of Patent: August 2, 1994
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, Kenneth S. Hirsch, Charles D. Jones, David E. Lawhorn, Loretta A. McQuaid, Leland O. Weigel
  • Tetrahydro-pyrido-indole
    Patent number: 5300645
    Abstract: The present invention provides a new Pictet-Spengler process useful for preparing tetrahydro-beta-carboline compounds.
    Type: Grant
    Filed: April 14, 1993
    Date of Patent: April 5, 1994
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, James J. Droste, Deborah A. Evrard